Konvomep (Omeprazole/Sodium Bicarbonate) Patent Expiration, LOE Window & CMS Spending

Konvomep (Omeprazole/Sodium Bicarbonate) by Azurity: FDA Orange Book LOE 2040-03-01, 3 AB generics, $15.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN213593 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-03-01
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$15.1M
2024 Medicare Part D Spend$4.5M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel